Newsmeme!
Discover News you didn't know existed
Esophagus
News
XenoPort Reports Results from a Phase 2 Clinical Trial of XP19986 as a Treatment for the Symptoms of Gastroesophageal ...
Published December 2, 2008, 4:47 am, Centre Daily Times
XenoPort, Inc. (Nasdaq:XNPT) announced today top-line results from a Phase 2 clinical trial that examined the ability of XP19986 ( arbaclofen placarbil ) extended-release tablets to reduce symptoms experienced by subjects with gastroesophageal reflux disease, or GERD. The primary analysis comparing XP19986 to placebo did not reach statistical significance. However, pre-defined subgroup analyses ...
Tags
No tags found at this time. Be the first to tag this news item, learn more.
Imagery
Related Esophagus Stories
From Various News Sources
XenoPort Reports Results from a Phase 2 Clinical Trial of XP19986 as a ... - PR Inside
XenoPort, Inc. (Nasdaq:XNPT) announced today top-line results from a Phase 2 clinical trial that examined the ability of XP19986 (arbaclofen placarbil) extended-release tablets to reduce symptoms experienced by subjects with gastroesophageal reflux ...
Related Social Bookmarks
None found at this time.
Related News Resources:
> HGH News
News Directory
Get started fast by using a pre-defined news directory category
|
Breaking News
and Top Stories |
Business
Earnings, Economy, Personal Finance, and Stock Markets |
Entertainment
Books, Celebrity, Fashion, Movies, Music, Television, and Theatre |
Health
Aging, Diseases, Medical Conditions, Medications, Sexual Health, and Weight Loss |
Politics
Congress, Supreme Court, and White House |
|
Science
Animals, Astronomy, Biotechnology, Space, and Weather |
Sports
Baseball, Basketball, Boxing, Football, Golf, Hockey, Motor Sports, Soccer, and Tennis |
Technology
Communications, Hardware, Internet, Personal Technology, and Software |
United States
and Crimes and Trials |
World
Africa, Antartica, Asia, Australia, Canada, Europe, Latin America, and Middle East |